http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021349110-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_465b607edb4c88aeefb4958e154efaec |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2405-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-085 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 |
| filingDate | 2019-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87a8ab714407e88b9171de093dede677 |
| publicationDate | 2021-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2021349110-A1 |
| titleOfInvention | Method for providing information on diagnosis or prognostic measurement of histological severity of nonalcoholic fatty liver disease |
| abstract | The present invention relates to a method for providing information on a diagnosis or prognostic measurement of the histological severity of nonalcoholic fatty liver disease. Since the risk associated with the severity of nonalcoholic fatty liver disease can be considered to have increased when the content of sphingomyelin is at least 1.3 times higher than in a normal control group, the present invention can be effectively used for the diagnosis or prognostic measurement of severity. |
| priorityDate | 2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.